{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:01:10Z","timestamp":1789084870980,"version":"build-2803163510"},"reference-count":5,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2015,1,12]],"date-time":"2015-01-12T00:00:00Z","timestamp":1421020800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2015,4]]},"abstract":"<jats:p>\n                    The primary objective of this single\u2010centre, open\u2010label crossover study (\n                    <jats:styled-content style=\"fixed-case\">NCT01072578<\/jats:styled-content>\n                    ) was to assess the effect of dapagliflozin on the amount of glucose in the blood and urine in healthy volunteers when dapagliflozin was administered once a day (10\u2009mg) versus twice a day (5\u2009mg every 12\u2009h) after 5\u2009days of dosing. At steady state, the AUC\n                    <jats:sub>ss (0\u201024)<\/jats:sub>\n                    (area under the dapagliflozin curve (0\u201024 hours) at steady state), C\n                    <jats:sub>ss, av<\/jats:sub>\n                    (average concentration at steady state) between dapagliflozin 5\u2009mg twice daily and 10\u2009mg once daily were similar AUC\n                    <jats:sub>ss(0\u201024)<\/jats:sub>\n                    [5 mg bid, (458.0 (28.7)) and 10 mg qd, (470.0 (28.5))] and C\n                    <jats:sub>ss, av<\/jats:sub>\n                    [5 mg bid 18.8 (28.9)) and 10 mg qd, (19.6(28.5))], but minimum and maximum plasma levels of dapagliflozin differed significantly. Percent inhibition of renal glucose reabsorption (%\n                    <jats:styled-content style=\"fixed-case\">IRGRA<\/jats:styled-content>\n                    ) and total urinary glucose excretion over 24\u2009h were similar for both doses. The relationship between the mean dapagliflozin concentration and %\n                    <jats:styled-content style=\"fixed-case\">IRGRA<\/jats:styled-content>\n                    and the total urinary glucose excreted was well described by a maximum effect model. The results indicate that dapagliflozin may be used for either once daily or twice daily administration.\n                  <\/jats:p>","DOI":"10.1111\/dom.12425","type":"journal-article","created":{"date-parts":[[2014,12,16]],"date-time":"2014-12-16T02:34:33Z","timestamp":1418697273000},"page":"423-425","source":"Crossref","is-referenced-by-count":17,"title":["Dapagliflozin twice daily or once daily: effect on pharmacokinetics and urinary glucose excretion in healthy subjects"],"prefix":"10.1111","volume":"17","author":[{"given":"W.","family":"Tang","sequence":"first","affiliation":[{"name":"AstraZeneca, R&amp;D  Wilmington DE USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Reele","sequence":"additional","affiliation":[{"name":"Reele Consulting, LLC  Scottsville VA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. E.","family":"Hamer\u2010Maansson","sequence":"additional","affiliation":[{"name":"AstraZeneca, R&amp;D  Wilmington DE USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Parikh","sequence":"additional","affiliation":[{"name":"AstraZeneca, R&amp;D  Wilmington DE USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. W. A.","family":"de Bruin","sequence":"additional","affiliation":[{"name":"AstraZeneca, R&amp;D  Wilmington DE USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,1,12]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm701272q"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2008.12.031"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60407-2"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01434.x"},{"key":"e_1_2_7_6_1","unstructured":"Dapagliflozin (Forxiga).Summary of product characteristics. European Medicines Agency Web site.2012. Available from URL:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_\u2010_Product_Information\/human\/002322\/WC500136026.pdf. Accessed 11 October 2013."}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.12425","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.12425","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T04:57:59Z","timestamp":1761886679000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.12425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,12]]},"references-count":5,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["10.1111\/dom.12425"],"URL":"https:\/\/doi.org\/10.1111\/dom.12425","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,12]]}}}